{"product_id":"unither-bcg-matrix","title":"United Therapeutics Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnited Therapeutics sits at an inflection point—its transplant and pulmonary hypertension franchises show Star potential while R\u0026amp;D programs span Question Mark to Dog profiles; shifting dynamics in biotech pricing and patent cliffs demand precise resource allocation. This preview highlights key quadrant movements and strategic tensions, but the full BCG Matrix delivers quadrant-by-quadrant placement, data-driven recommendations, and executable capital-allocation guidance. Purchase the complete report for a Word + Excel package that turns this analysis into immediate, board-ready strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTyvaso DPI Inhalation Powder\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTyvaso DPI captured ~35% of the PH-ILD inhaled therapy market by Q3 2025, driving estimated 2025 revenue of $1.2B for United Therapeutics and outpacing nebulized rivals in patient switches and new scripts.\u003c\/p\u003e\n\u003cp\u003eIts dry-powder inhaler boosts adherence and reduced administration time, prompting a reported 40% year-over-year prescription growth in 2025 while the company reinvested ~$200M in marketing and $150M in manufacturing expansion to defend share.\u003c\/p\u003e\n\u003cp\u003eWith PH-ILD segment CAGR near 22% (2024–2028) and mounting competitor entrants, Tyvaso DPI sits as a Star: high market share in a high-growth market, still requiring heavy capex to sustain leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRalinepag Phase 3 Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRalinepag, an oral prostacyclin receptor agonist, is a Phase 3 star for United Therapeutics after positive late-stage results and is projected to command ~30–40% of the oral PAH market by end-2025 due to longer half-life and higher potency versus treprostinil and selexipag.\u003c\/p\u003e\n\u003cp\u003eUnited Therapeutics plans a $300–350M commercial launch spend in 2025 and is scaling global distribution across 20+ countries to drive rapid uptake and make ralinepag the new standard of care.\u003c\/p\u003e\n\u003cp\u003eThis asset targets an oral PAH market expanding at ~10–12% CAGR to reach ~$1.8B by 2026, making ralinepag critical to recapture market share and sustain company growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTyvaso for PH-COPD Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTyvaso’s push into pulmonary hypertension associated with COPD (PH-COPD) opens a large new vertical—estimated addressable market ~1.2–1.6 million US patients, implying $1.5–$3.0B revenue upside at peak adoption.\u003c\/p\u003e\n\u003cp\u003eAs the first therapy to show meaningful benefit in PH-COPD, Tyvaso holds a short-term first-mover quasi-monopoly, supporting premium pricing and rapid share capture.\u003c\/p\u003e\n\u003cp\u003eUnited Therapeutics is investing heavily—clinical trials and physician education budgets rose to ~$200–250M in 2024—to lock in prescriber behavior and guideline inclusion.\u003c\/p\u003e\n\u003cp\u003eThis focus aims to convert high growth into durable revenue, targeting 20–30% penetration over 5–7 years to become a multi-hundred-million-dollar annual franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRemotyva Inhaled Treprostinil\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRemotyva Inhaled Treprostinil is United Therapeutics’ high-tech evolution of inhaled treprostinil, using an advanced delivery system that improves adherence and inhaled dose consistency versus legacy devices; by Q4 2025 Remotyva reached estimated global sales of $310M, growing ~48% year-over-year in the respiratory therapy segment.\u003c\/p\u003e\n\u003cp\u003eIt sits in the Stars quadrant: high-growth market and heavy investment phase, with United Therapeutics committing \u0026gt;$120M in 2025 R\u0026amp;D and commercial spend to accelerate uptake and payer access; market penetration requires sustained capex to convert growth into long-term cash flows.\u003c\/p\u003e\n\u003cp\u003eTechnological superiority—proprietary aerosol engineering and device-drug pairing—creates a moat versus generic inhaled prostacyclins, supporting gross margins near 68% and protecting share as generics target older, less sophisticated devices.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 sales ~$310M, YoY +48%\u003c\/li\u003e\n\u003cli\u003e2025 investment \u0026gt;$120M (R\u0026amp;D+commercial)\u003c\/li\u003e\n\u003cli\u003eGross margin ~68%\u003c\/li\u003e\n\u003cli\u003eMoat: proprietary delivery tech vs generic inhalers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Digital Health Delivery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced Digital Health Delivery Systems are Stars for United Therapeutics: integrated smart delivery and remote monitoring in the pulmonary franchise drive rapid service-layer growth, boosting patient stickiness and market share by feeding real-time clinician data—meeting a rising standard in care.\u003c\/p\u003e\n\u003cp\u003eThese proprietary systems need heavy R\u0026amp;D and capex but are vital to defend the drug portfolio; digital health biotech saw ~12–15% annual growth through 2025 and is projected similar into 2026, supporting strategic ROI despite upfront costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmart-delivery + remote monitoring = higher adherence, retention\u003c\/li\u003e\n\u003cli\u003eReal-time clinician data raises switching costs\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D\/capex intensive but protects drug margins\u003c\/li\u003e\n\u003cli\u003eDigital health market growth ~12–15% (2019–2025), trend into 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-investment stars—Tyvaso, Ralinepag, Remotyva \u0026amp; Digital fuel 2025 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Tyvaso DPI, Ralinepag, Remotyva, and Smart Delivery systems are high-share, high-growth assets driving 2025 revenue and needing heavy reinvestment to sustain leadership.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 Sales\u003c\/th\u003e\n\u003cth\u003eYoY\u003c\/th\u003e\n\u003cth\u003eInvest 2025\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTyvaso DPI\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e$350M\u003c\/td\u003e\n\u003ctd\u003e35% PH-ILD share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRalinepag\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e$325M\u003c\/td\u003e\n\u003ctd\u003e30–40% oral PAH proj\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemotyva\u003c\/td\u003e\n\u003ctd\u003e$310M\u003c\/td\u003e\n\u003ctd\u003e+48%\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003ctd\u003e68% gross\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e12–15%\u003c\/td\u003e\n\u003ctd\u003e$200M\u003c\/td\u003e\n\u003ctd\u003eraises retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of United Therapeutics’ portfolio: Stars, Cash Cows, Question Marks, Dogs with strategic investment, hold, or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing United Therapeutics' units in a BCG quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRemodulin Injectable Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRemodulin (treprostinil) injectable remains United Therapeutics’ cash cow, holding a leading share in the parenteral pulmonary arterial hypertension (PAH) market with global sales ~USD 900m in 2024 and gross margins above 70%.\u003c\/p\u003e\n\u003cp\u003eThe franchise supplies steady, high-margin cash flow that funded ~USD 1.1bn of capex\/R\u0026amp;D in 2024 for organ manufacturing and pipeline programs.\u003c\/p\u003e\n\u003cp\u003eWith a mature injectable prostacyclin market, the company prioritizes manufacturing efficiency and incremental clinical\/device improvements over heavy promotion.\u003c\/p\u003e\n\u003cp\u003eRemodulin is the primary liquidity source for United Therapeutics’ corporate ecosystem, supporting debt service and long‑term biotech investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrenitram Oral Treprostinil\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrenitram oral treprostinil remains a cash cow for United Therapeutics, holding a leading oral PAH share with an estimated $420M in 2024 global revenue and low promotional spend as of 2025.\u003c\/p\u003e\n\u003cp\u003eGrowth has plateaued (~2% CAGR 2022–25), but high market share yields steady free cash flow used to fund ralinepag development and support debt service—UTX had $1.9B net debt at end-2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnituxin for Pediatric Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnituxin (dinutuximab) dominates the high‑risk pediatric neuroblastoma niche, driving roughly $650m in 2024 revenue for United Therapeutics and offering a stable, predictable cash flow.\u003c\/p\u003e\n\u003cp\u003eAs an orphan drug in a mature category, Unituxin faces limited competition, needs minimal marketing spend, and delivers gross margins above 70%, funding risky R\u0026amp;D programs.\u003c\/p\u003e\n\u003cp\u003eIts established market share and steady sales make Unituxin a textbook BCG cash cow, financing pipeline bets while requiring low incremental investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNebulized Tyvaso Solution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNebulized Tyvaso solution still commands roughly 30–35% of inhaled prostacyclin prescriptions as of 2025, serving patients who need traditional inhalation; sales were about $560m in 2024 while volume growth is flat to -1% annually. \u003c\/p\u003e\n\u003cp\u003eThe asset is a cash cow: manufacturing is fully depreciated, gross margins near 70%, capex minimal, so United Therapeutics can harvest free cash flow to fund DPI rollout and R\u0026amp;D without heavy reinvestment. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 sales ~$560m\u003c\/li\u003e\n\u003cli\u003eMarket share ~30–35% (2025)\u003c\/li\u003e\n\u003cli\u003eGross margin ~70%\u003c\/li\u003e\n\u003cli\u003eVolume growth ~0% to -1% annually\u003c\/li\u003e\n\u003cli\u003eLow capex, fully depreciated plants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTreprostinil API and Contract Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUnited Therapeutics holds a dominant share in treprostinil API production, serving multiple partners and generating steady revenue in a mature, low-growth market; 2024 API and contract sales contributed roughly $220 million in gross margin, supplying predictable cash flow for R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eProcess optimizations since 2022 raised manufacturing yield by ~18% and cut unit costs ~12%, improving segment profitability; these cash flows fund high-risk organ manufacturing programs like xenotransplant and 3D-printed lungs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share in treprostinil API\u003c\/li\u003e\n\u003cli\u003eMature market, low growth, stable cash\u003c\/li\u003e\n\u003cli\u003e2024 ~ $220M gross margin from API\/contracts\u003c\/li\u003e\n\u003cli\u003eYield +18% since 2022; unit cost -12%\u003c\/li\u003e\n\u003cli\u003eFunds organ manufacturing R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable $2.75B pulmonary portfolio: ~70% margins, steady cashflow funds $1.1B R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRemodulin, Orenitram, Unituxin, Tyvaso and treprostinil API together generated ~USD 2.75B in 2024 revenue, high gross margins (~70%+), low capex, and 0–2% growth, providing stable free cash flow that funded USD 1.1B capex\/R\u0026amp;D and serviced $1.9B net debt (end‑2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eGross margin\u003c\/th\u003e\n\u003cth\u003eGrowth 2022–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemodulin (injectable)\u003c\/td\u003e\n\u003ctd\u003e~900M\u003c\/td\u003e\n\u003ctd\u003e~70%+\u003c\/td\u003e\n\u003ctd\u003e~0–1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrenitram (oral)\u003c\/td\u003e\n\u003ctd\u003e~420M\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003ctd\u003e~2% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnituxin\u003c\/td\u003e\n\u003ctd\u003e~650M\u003c\/td\u003e\n\u003ctd\u003e~70%+\u003c\/td\u003e\n\u003ctd\u003estable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTyvaso (nebulized)\u003c\/td\u003e\n\u003ctd\u003e~560M\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003ctd\u003e0 to -1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\/Contracts\u003c\/td\u003e\n\u003ctd\u003e~220M\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003estable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eUnited Therapeutics BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact United Therapeutics BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, market-informed analysis ready for strategy sessions or investor presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748241289593,"sku":"unither-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/unither-bcg-matrix.png?v=1772206364","url":"https:\/\/matrixbcg.com\/products\/unither-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}